Yahoo Web Search

Search results

1. • Introducing Cannovation Clinical Research Partners, LLC: Pioneering the Future of BioPharmaceutical...

     Digital Journal· 7 hours ago

     "Cannovation Clinical Research Partners, LLC serves as a vital bridge between these industries, facilitating the development and commercialization

2. • ...Dr. Vince Clinical Research Appoints World-Renowned...Renowned Drug Developer, Clinical...

     The Morning Sun· 13 hours ago

     OVERLAND PARK, Kan.--(BUSINESS WIRE)--May 8, 2024--Dr. Vince Clinical Research (DVCR), a full-service contract research organization ...

3. • 

     Pfizer reports fatality in Phase II DMD gene therapy study

     Clinical Trials Arena via Yahoo Finance· 7 hours ago

     Pfizer concluded the initial dosing of subjects in placebo-controlled, randomised crossover...

4. • FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302

     Digital Journal· 1 day ago

     Andrzej Chruscinski, Vice-President, Scientific and...wholly-owned subsidiary, Lucid Psycheceuticals Inc. (" Lucid "), FSD is focused on the research and development

5. • Vigil Neuroscience Inc (VIGL) Q1 2024 Earnings: Challenges Persist Amid Clinical Developments

     GuruFocus.com via Yahoo Finance· 16 hours ago

     This performance reflects ongoing investments in research and development as the company advances its clinical programs. Company Overview Vigil Neuroscience ...

6. • Q1 2024 Ionis Pharmaceuticals Inc Earnings Call

     Thomson Reuters StreetEvents via Yahoo Finance· 8 hours ago

     The study also met other important secondary endpoints and had a favorable safety and tolerability profile. We're looking forward to presenting data from the Phase III OASIS ...

7. • X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...

     GuruFocus.com via Yahoo Finance· 10 hours ago

     Research and Development Expenses: $19.9 million for Q1... Date: May 07, 2024 For the complete transcript of the earnings call, please refer to the full ...

8. • NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor...

     NBC 17 Raleigh· 5 hours ago

     M4 PAM presents a novel approach to treating schizophrenia...

9. • Gameto Announces New Data Demonstrating Clinical-Grade Manufacturing of In Vitro Maturation Solution...

     KOLR - KSFX Ozarks· 2 hours ago

     "This study is the first to demonstrate the end-to-end process by which...fertilization (IVF) outcomes and advance women's health, paving the way for its application in clinical< ...

10. • 

      Teva Pharma's Turnaround Story: How A Key Win Helped It Clinch A Five-Year High

      Investor's Business Daily· 4 minutes ago

      Teva also affirmed its full-year view for $15.7 billion to $16.3 billion in sales. The midpoint of...